{
    "nctId": "NCT02137083",
    "briefTitle": "A Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Metastatic Breast Cancer",
    "officialTitle": "A Prospective Single-center Randomized Phase 2 Trial Comparing Docetaxel Plus Fulvestrant With Docetaxel in Postmenopausal, Hormone-receptor Positive and HER2-negative Metastatic Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 22,
    "primaryOutcomeMeasure": "Progression Free Survival",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Postmenopausal female between 18 and 70 years old\n* ECOG performance status of \u2264 1\n* Life expectancy more than 3 months\n* Histologically confirmed metastatic breast cancer\n* ER and\\&or PR pqositive, HER2-negative\n* Disease progression during adjuvant or first-line endocrine therapy, or endocrine naive but unsuitable for endocrine therapy alone\n* No pretreated chemotherapy for metastatic disease\n* Have at least one target lesion according to RECIST 1.1\n* No therapy (chemotherapy, endocrine therapy, target therapy and operation) within 4 weeks before enrollment\n* Hemoglobin \u2265 90 g/L, Absolute Neutrophil Count \u2265 1.5\u00d710\\^9/L, Platelet Count \u2265 75\u00d710\\^9/L, Serum Bilirubin \u2264 1.5\u00d7ULN, ALT and AST \u2264 1.5\u00d7ULN, Serum Creatinine \u2264 1\u00d7ULN, Endogenous Creatinine Clearance\\>50ml/min\n\nExclusion Criteria:\n\n* Pregnant or lactating women\n* Evidence of CNS metastasis\n* Seriously uncontrolled infection\n* History of another malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix\n* Pretreated with Fulvestrant\n* Pretreated with two or more lines of endocrine therapy",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}